CAMBRIDGE, MA, United States

Molecular Insight Pharmaceuticals, Inc.

www.molecularinsight.com
CAMBRIDGE, MA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Molecular Insight Pharmaceuticals, Inc. | Date: 2017-07-26

A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.


Patent
Molecular Insight Pharmaceuticals, Inc. | Date: 2016-10-28

Compounds of Formula (Ia)


Patent
Molecular Insight Pharmaceuticals, Inc. | Date: 2015-11-11

Compounds of Formula (Ia)_(6)-C_(12) substituted or unsubstituted aryl, a C_(6)-C_(12) substituted or unsubstituted heteroaryl, a C_(1)-C_(6) substituted or unsubstituted alkyl or -NRR,Q is C(O), O, NR, S, S(O)_(2), C(O)_(2) (CH2)pY is C(O), O, NR, S, S(O)_(2), C(O)_(2) (CH2)pZ is H or C_(1)-C_(4) alkyl,R is H, C(O), S(O)_(2), C(O)_(2), a C_(6)-C_(12) substituted or unsubstituted aryl, a C_(6)-C_(12) substituted or unsubstituted heteroaryl or a C_(1)-C_(6) substituted or unsubstituted alkyl,when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C_(6)-C_(12) heteroaryl, - NRR or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.


Patent
Molecular Insight Pharmaceuticals, Inc. | Date: 2016-03-14

Compounds of Formula (Ia) wherein R is a C_(6)-C_(12 )substituted or unsubstituted aryl, a C_(6)-C_(12 )substituted or unsubstituted heteroaryl, a C_(1)-C_(6 )substituted or unsubstituted alkyl or NRR,


Patent
Molecular Insight Pharmaceuticals, Inc. | Date: 2015-01-14

Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which is capable of binding the active catalytic site of CA- IX, and a radionuclide adapted for radio-imaging and/or radiotherapy.


Patent
Molecular Insight Pharmaceuticals, Inc. | Date: 2016-08-10

Compounds according to Formula I and Formula II are potent inhibitors of PSMA. Pharmaceutical compositions may include a complex of a radionuclide and a Formula I compound or a Formula II compound. Methods include using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.


Patent
Molecular Insight Pharmaceuticals, Inc. | Date: 2015-09-04

A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.


Patent
Molecular Insight Pharmaceuticals, Inc. | Date: 2015-10-23

The present disclosure provides purified forms of iobenguane and preparations of a precursor to iobenguane, such as a polymer, the polymer comprising a monomer of formula (I) or a pharmaceutically acceptable salt thereof, the preparation comprising leachable tin at a level of 0 ppm to 850 ppm.


Patent
Molecular Insight Pharmaceuticals, Inc. | Date: 2016-01-06

One aspect of the invention relates to novel complexes of technetium (Tc) with various heteroaromatic ligands, e.g., pyridyl and imidazolyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to novel pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium complexes are also described. Another aspect of the invention relates to novel pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.


Patent
Molecular Insight Pharmaceuticals, Inc. | Date: 2015-01-30

A method of imaging a region in a subject includes administering to the subject a complex of a metal chelated to a compound, and obtaining an image of the region in the subject.

Loading Molecular Insight Pharmaceuticals, Inc. collaborators
Loading Molecular Insight Pharmaceuticals, Inc. collaborators